Effect of intraocular plasmin injection, in diabetic macular edema

Effect of intravitreal autologous plasmin injection, in treatment of diffuse diabetic macular edema

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015050522112N1

Enrollment

Registered

2015-06-17

Start date

2015-03-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus. Background retinopathy and retinal vascular changes

Interventions

Intervention 1: One time injection of autologous serum plasmin, 0.2 ml intravitreal. Intervention 2: Without any intervention, in cotrole group.

Treatment - Drugs

One time injection of autologous serum plasmin, 0.2 ml intravitreal

Without any intervention, in cotrole group.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Diabetic patients suffer from diffuse diabetic macular edema. Exclusion criteria: Uncontrolled hypertension; Unstable blood sugar level; Renal failure; History of Ocular hypertension and, Glaucoma; Ischemic macular or peripheral Retina; History of ocular surgery in last 6 month; Posterior vitreous detachment; Proliferative diabetic retinopathy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Central macular thickness. Timepoint: Befor intervention, 1month, and 2 month later. Method of measurement: Ocular cohrent tomography.;Visual acuity. Timepoint: Befor intervention, 1momth, and 2month later. Method of measurement: Snelen chart.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ali Hamidian Shoormasti

Alzahra Eye Hospital, Zahedan

Alihamidian1@yahoo.com+98 21 2257 7263

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026